JPMorgan Chase & Co. Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage set an “overweight” rating and a $31.00 price target on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 70.70% from the stock’s current price.

Other equities research analysts have also issued reports about the company. UBS Group began coverage on First Tracks Biotherapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price objective for the company. Barclays began coverage on First Tracks Biotherapeutics in a research note on Wednesday. They issued an “overweight” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, First Tracks Biotherapeutics has an average rating of “Buy” and an average target price of $38.40.

First Tracks Biotherapeutics Stock Performance

NASDAQ:TRAX opened at $18.16 on Thursday. First Tracks Biotherapeutics has a one year low of $14.79 and a one year high of $26.80.